# To Evaluate the Safety of JL18008

> **NCT07629310** · PHASE1 · COMPLETED · sponsor: **Jecho Biopharmaceuticals Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** JL18008 1 μg/kg
- **DRUG:** JL18008 5 μg/kg
- **DRUG:** JL18008 10 μg/kg
- **DRUG:** JL18008 20 μg/kg
- **DRUG:** JL18008 40 μg/kg
- **DRUG:** JL18008 70 μg/kg
- **DRUG:** Placebo (for 1 μg/kg Group)
- **DRUG:** Placebo (for 5 μg/kg Group)
- **DRUG:** Placebo (for 10 μg/kg Group)
- **DRUG:** Placebo (for 20 μg/kg Group)
- **DRUG:** Placebo (for 40 μg/kg Group)
- **DRUG:** Placebo (for 70 μg/kg Group)

## Key facts

- **NCT ID:** NCT07629310
- **Lead sponsor:** Jecho Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-13
- **Primary completion:** 2025-08-05
- **Final completion:** 2025-08-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07629310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07629310, "To Evaluate the Safety of JL18008". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07629310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*